Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kristina Cochrane"'
Autor:
Sergio Bergese, Richard Berkowitz, Paul Rider, Martin Ladouceur, Suzanne Griffith, Alvaro Segura Vasi, Kristina Cochrane, Linda Wase, Mark A. Demitrack, Ashraf S. Habib
Publikováno v:
Pain Research and Management, Vol 2020 (2020)
Background. Oliceridine, an investigational IV opioid, is a first-in-class G-protein selective agonist at the μ-opioid receptor. The G-protein selectivity results in potent analgesia with less recruitment of β-arrestin, a signaling pathway associat
Externí odkaz:
https://doaj.org/article/01834d681ffc4e618cdc85e41ebfbf34
Autor:
Gregory B. Hammer, Sergio D. Bergese, Richard D Berkowitz, Peter H. Pan, Marek Brzezinski, Harold S. Minkowitz, Ashraf S. Habib, Linda Wase, Timothy L Beard, Sharon E. Mace, Kristina Cochrane
Publikováno v:
Journal of Pain Research
Sergio D Bergese,1 Marek Brzezinski,2 Gregory B Hammer,3 Timothy L Beard,4 Peter H Pan,5 Sharon E Mace,6 Richard D Berkowitz,7 Kristina Cochrane,8 Linda Wase,8 Harold S Minkowitz,9 Ashraf S Habib10 1School of Medicine, Stony Brook University, Stony B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::954d14b3ba826990cf92ed0e6c2703ef
https://doi.org/10.2147/jpr.s217563
https://doi.org/10.2147/jpr.s217563
Autor:
Paul Rider, Richard D Berkowitz, Martin Ladouceur, Mark A. Demitrack, Linda Wase, Suzanne Griffith, Sergio D. Bergese, Kristina Cochrane, Ashraf S. Habib, Alvaro Segura Vasi
Publikováno v:
Pain Research & Management
Pain Research and Management, Vol 2020 (2020)
Pain Research and Management, Vol 2020 (2020)
Background. Oliceridine, an investigational IV opioid, is a first-in-class G-protein selective agonist at the μ-opioid receptor. The G-protein selectivity results in potent analgesia with less recruitment of β-arrestin, a signaling pathway associat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2480563da2d7ce80e4f4c8e05d22f5f0
http://europepmc.org/articles/PMC7604609
http://europepmc.org/articles/PMC7604609
Autor:
Michael J. Fossler, Kelly A. Arscott, David A. Burt, Franck Skobieranda, Kristina Cochrane, Anne N. Nafziger
Publikováno v:
Clinical Pharmacology in Drug Development
Oliceridine is a G protein–biased ligand at the μ‐opioid receptor in development for treatment of moderate to severe acute pain. A phase 1, open‐label, single‐dose study investigated the pharmacokinetics and safety of oliceridine 0.5 mg intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::899d4327a8282815e199d45a7f0100c9
https://pubmed.ncbi.nlm.nih.gov/31697049
https://pubmed.ncbi.nlm.nih.gov/31697049